FDA has approved Utebzi (tebipenem pivoxil), the first oral carbapenem in the U.S., for adults with complicated urinary tract infections. Approval was based on Phase III PIVOT-PO trial results demonstrating non-inferiority to intravenous imipenem-cilastatin
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) has approved Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic in the United States, for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral treatment options. The approval introduces an oral alternative to intravenous carbapenem therapy, which has historically required hospitalization or outpatient infusion services.
Unmet Need in cUTI Treatment
Carbapenems are among the most reliable antibiotics for treating multidrug-resistant Gram-negative infections. Until now, all carbapenem options available in the U.S. required intravenous administration.
More than three million cUTI cases are treated annually in the United States, with resistant infections contributing to treatment failures, prolonged hospital stays, and rising healthcare costs. An oral carbapenem offers the potential to shift appropriate patients from inpatient to outpatient care while maintaining access to a critical antibiotic class.
About Utebzi (Tebipenem Pivoxil)
Tebipenem pivoxil is an oral carbapenem antibiotic active against several bacterial pathogens commonly associated with complicated urinary tract infections, including Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, and Enterococcus faecalis. The therapy previously received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations, reflecting the urgent need for new treatments targeting resistant bacterial infections.
Phase III PIVOT-PO Trial
Approval was supported by the global Phase III PIVOT-PO trial (NCT06059846), a randomized, double-blind, non-inferiority study comparing oral tebipenem pivoxil with intravenous imipenem-cilastatin in 1,690 hospitalized adults with cUTIs, including acute pyelonephritis.
Patients received oral tebipenem pivoxil 600 mg every six hours or intravenous imipenem-cilastatin 500 mg every six hours for seven to ten days.
The primary endpoint was overall response at the test-of-cure visit, defined as a composite of clinical cure and microbiological eradication.
Key results included:
- Overall success rate: 58.5% with tebipenem pivoxil versus 60.2% with imipenem-cilastatin
- Adjusted treatment difference: −1.3% (95% CI: −7.5% to 4.8%)
The study met its predefined non-inferiority criteria, demonstrating that oral tebipenem provided efficacy comparable to the intravenous carbapenem standard of care.
Safety Profile
Tebipenem’s safety profile was generally consistent with other carbapenem antibiotics. The most commonly reported adverse events occurring in at least 3% of patients were diarrhea and headache. These events were typically mild to moderate in severity, and no unexpected safety signals emerged during the study.
Strategic Importance
The approval represents a major milestone for Spero Therapeutics, which advanced tebipenem pivoxil through more than a decade of development, and for GSK, which acquired global commercialization rights outside select Asian territories in 2022.
Tony Wood, GSK’s Chief Scientific Officer, said the approval provides the first oral carbapenem option for eligible adults with complicated UTIs and could help reduce reliance on hospital-based intravenous treatment while addressing resistant infections.
Esther Rajavelu, CEO of Spero Therapeutics, said the approval marks the culmination of more than a decade of development and will help bring a much-needed oral treatment option to patients with complicated urinary tract infections.
Availability and Clinical Implications
GSK expects Utebzi to become available in the United States by the end of 2026. The launch expands the company’s anti-infectives portfolio and provides physicians with a new outpatient treatment option for resistant cUTIs.
As antimicrobial resistance continues to threaten the effectiveness of existing antibiotics, the availability of the first oral carbapenem may help reduce hospital resource utilization while maintaining access to one of the most important classes of antibacterial therapy.
What This Means for Patients
For patients with complicated urinary tract infections, especially those caused by antibiotic-resistant bacteria, the approval of Utebzi offers a new oral treatment option that may reduce the need for prolonged hospital stays or intravenous antibiotic infusions. As the first oral carbapenem available in the United States, it has the potential to make treatment more convenient for eligible patients while providing access to a highly effective antibiotic class traditionally limited to hospital settings. However, Utebzi is intended for specific patients with limited or no alternative oral treatment options, and treatment decisions should be guided by a healthcare professional.
Reference
FDA approves first oral carbapenem therapy for complicated urinary tract infections | FDA
About the Writer
Sana Jamil Khan (LinkedIn) is a B. Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.